News & Press Releases

September 21, 2021 04:05 PM ET

Pardes Bioscience Announces Issuance of Its First U.S. Patent

CARLSBAD, Calif., Sept. 21, 2021 -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new patent No. 11,124,497 (the “’497 patent”), strengthening the Company’s intellectual property position for the Company’s antiviral drug development program.
Read More
August 26, 2021 08:00 AM ET

Pardes Biosciences Initiates First-in-Human Trial forPBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2Infections

CARLSBAD, Calif., Aug. 26, 2021 -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19.
Read More
August 05, 2021 07:00 AM ET

Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors

CARLSBAD, Calif., Aug. 05, 2021 --(GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors.
Read More
June 29, 2021 06:00 AM EDT

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

CARLSBAD, Calif. & LARKSPUR, Calif.--(BUSINESS WIRE)-- Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the company will be renamed “Pardes Biosciences, Inc.” (Combined Company) and will be led by Uri A. Lopatin, M.D., Chief Executive Officer of Pardes. The Combined Company’s common stock is expected to be listed on NASDAQ under the ticker symbol PRDS.
Read More

Recent Presentations

June 7-8, 2021

NIDO Conference: Presenter Dr. Mark Denison, Vanderbilt University, Novel Protease Inhibitors as Potent Broad-Spectrum Coronavirus Antivirals